Hifibio SAS

In 2021, Bivision Pharmaceuticals (hereinafter referred to as "Bivision") was co-founded by Dr.Haihua Yu, Dr.Yu Wang and other two biotech veterans. Dr.Haihua Yu worked in GSK for more than 10 years in new drug research and development, and later joined Huayi Technology to take charge of Molecular Imaging and Drug Research Institute; Dr.Yu Wang has been engaged in small molecule nuclear drugs and other targeted coupling drug research and development for more than 20 years in Endocyte (which has been acquired by Novartis) and Eli Lilly and other international well-known pharmaceutical companies, and has experience in new drug research and development of several NDA and IND in the United States. This round of financing will be used to accelerate the preclinical development of multiple innovative nuclear drugs and carry out Clinical phase 1 studies of the fastest pipeline, and upgrade the nuclear drug research and development platform to further consolidate its leading position in the field of targeted nuclear drugs. 01 Dr.Haihua Yu, co-founder and CEO of Bivision, said: "This time by GaoRong Capital, VI Ventures and other international well-known venture capital institutions a new round of investment, but also by the old shareholders continue to trust and support, in the" capital winter "environment is not only the recognition and affirmation of the Bivision team and projects, but also for the visual diagnosis and treatment of integrated targeted nuclear drugs field. Visual diagnosis and treatment integrated targeted nuclear drugs through the use of PET/CT and other equipment can not only achieve systemic dynamic, non-invasive early visual diagnosis and rating, but also achieve the evaluation of therapeutic effect; At the same time, targeted radiotherapies (TRT) fully combine the advantages of targeted drugs and physical rays, and solve the current clinical pain points from the aspects of drug dosage, safety and overcoming drug resistance, providing a new drug choice for patients at home and abroad.” 02 Dr. Jingyi Liu of GaoRong Capital, said: "As a new type of differentiated treatment worldwide, targeted nuclear drugs have a very broad market prospect. As an emerging field, the development ideas and screening evaluation of targeted nuclear drugs are quite different from those of traditional drugs, facing more problems and challenges, and higher technical barriers. The founding team of Bivision Biological comes from the industry's star enterprises Endocyte/Novartis, Siemens, GSK, Huayi, etc., and has the research and development experience of international listed nuclear drugs. I believe that the team can make full use of the advantages of the technology platform, accelerate the development process of product pipeline, and bring new hope to the global patients as soon as possible." 03 Guangwei Yu, Executive President of KaiTai Capital, said: "The co-founding team of Bivision has the global first-line level of targeted nuclide drug research and development experience, from the pre-clinical targeting ligand screening, coupling technology application, radiopharmaceutics optimization, thermochemical CMC and other whole process development experience, while using its own multi-functional coupling technology platform (J-Linker), It provides a strong and favorable innovation source and competitive advantage for the later research and development of Crystal karyotes." 04 Wenzhe Zhou from VI Ventures said: "Therapeutic targeted nuclear drugs is a high threshold, high access field, is still a relatively new track, from the number of drugs have been listed at home and abroad, this field is still a blue ocean, with great market prospects. The new field means new challenges, and I believe that the team of Bivision has the strength to stand out from this field and become a global leader in this field." About Bivision: Founded in 2021, Bivision is an innovative biotech company committed to develop the next generation of targeted radionuclide therapy (TRT). Bivision was founded by a group of biotech veterans who have extensive experience and track record in the field of targeted radionuclide therapy. Their hands-on experience and vision to develop new radiopharmaceuticals build up a solid foundation for Bivision to plan and execute its TRT drug discovery and development projects. Since its inception, the key proprietary technology platforms for nuclear drug development were built in the aspect of ligand screening, linker conjugation (J-Linker technology) and clinical transformation. The synchronous development and effective integration of these platforms are the core driving force for the rapid advancement of the product pipeline. The company's first drug candidate is currently under clinical development. About GaoRong Capital GaoRong Capital focuses on early stage and growth stage investment, focusing on new consumption, new technology, healthcare and other innovative and entrepreneurial fields. In the medical and health field, it invests in excellent enterprises in the fields of digital health, medical services, new drug research and development, medical devices and testing; In the field of new technology, GaoRong is deeply engaged in new technology fields such as artificial intelligence, intelligent hardware, robots, chips, enterprise services and industrial upgrading; In the field of new consumption, we continue to look for opportunities in the fields of "new e-commerce", "new retail", "new brand", "new entertainment" and "new infrastructure". Up to now, GaoRong has invested in more than 200 companies at home and abroad, 20+ companies have gone public, and 30+ unicorns have been valued at more than $1 billion. About KaiTai Capital KaiTai Capital is an innovative capital management institution that focuses on investments in biomedicine and life sciences, artificial intelligence and digital technology, data intelligence and technology consumption. In the field of biomedicine and life science, with a global vision, forward-looking industry research and industrial ecological investment concept, KaiTai Capital has invested in more than 100 domestic and foreign biomedicine and life science enterprises, and initially formed an industrial cooperation ecology. It has formed an ecological investment portfolio in the fields of tumor, autoimmune disease, metabolic disease, anti-infection, respiratory disease, cardiovascular disease, neuroscience, kidney disease, ophthalmology, skin, gene therapy and cell medicine, pharmaceutical industry, innovative biotechnology and large health industry. About YiJing Capital YiJing Capital founded in 2015 and headquartered in Shanghai, is a professional investment institution focusing on global medical health, frontier technology and new consumer fields, and operates parent fund investment in the above fields. The company adheres to the concept of "helping enterprises innovate and grow, promoting industrial optimization and upgrading, and promoting social development and progress". So far, the management scale has reached 8 billion yuan, and there are 8 recognized unicorn enterprises in the industry. In the investment projects of YiJing Capital, many enterprises have developed into influential leading enterprises in their respective segments. In the medical and health fields, including HanYu Medical, Our United Corp., OPM Biosciencesi, Medsci, Wellem, etc.; New consumption areas include Tasogare, Zhiketong and so on. About VI Ventures VI Ventures focuses on domestic and overseas companies with entrepreneurial enthusiasm and leading technology, providing seed, start-up and growth stage funding. It mainly invests in biomedicine, medical device and biotech and TMT sectors, with investments in China, the United States and Israel. It aims to help foreign companies in its portfolio access the booming Chinese market, while building Bridges for domestic companies to expand their business overseas. Angel Round incubation or early stage portfolios include: Hifibio, Viracta Therapeutics, Rani Therapeutics, Aadi biosciences, Tongee Medical, Human Metabolomics, Freshwind Biotech, Platelet Biogenesis, HocerMed, Apexigen, Tyligand Bioscience, TriArm, ACXEL, etc.

CAMBRIDGE, Mass. – Apr 16, 2024 – HiFiBiO Therapeutics, a clinical stage biotech company focusing on improving patient lives with single cell precision, today announced a new grant awarded by the Patient-Led Research Fund, a project of Patient-Led Research Collaborative and funded by Balvi. This grant is dedicated to a research initiative in collaboration with UMass Chan Medical School. The research will leverage HiFiBiO’s Drug Intelligence Science (DIS®) platform for single cell profiling to analyze samples from patients afflicted with neuroinflammatory and infection-associated chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID. The collaborative initiative includes Liisa Selin, MD, PhD, professor of pathology, and Anna Gil, PhD, instructor of pathology, at UMass Chan. Francisco Adrian, PhD, HiFiBiO’s Chief Scientific Officer, stated, “We are proud to have our advanced research capabilities recognized through this grant. Our partnership with UMass Chan is aimed at developing a comprehensive understanding of disease biology, particularly focusing on enhancing patient care for challenging diagnoses like long COVID and ME/CFS.” Roshan Kumar, PhD, HiFiBiO’s Executive Director of External Innovation, added, “Working alongside Drs. Selin and Gil is an exciting endeavor. The grant allows us to thoroughly investigate the immune mechanisms underlying these illnesses and to characterize patient immune responses at single-cell resolution. We are hopeful our findings will identify new diagnostic markers and pave the way for therapeutic breakthroughs.” Dr. Selin added, “We are thrilled to be collaborating with Dr. Kumar and HiFiBiO Therapeutics. We share the same goal: to shine the light of good science onto infection-associated chronic illnesses and make a positive impact on the lives of patients.” Project Title: Immune repertoire profiling of long COVID and ME/CFS patients Investigators: Roshan Kumar, PhD, HiFiBiO Therapeutics; Liisa Selin, MD, PhD, and Anna Gil, PhD, UMass Chan Medical School Patient Representatives: Megan Fitzgerald, PhD; Rivka Solomon, MS Project Description: Multiple lines of evidence point to underlying immune abnormalities in patients with post-viral and infection-associated illnesses, such as long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). However, how these abnormalities relate to disease symptoms and mechanisms is unclear. In some instances, autoimmunity may underlie chronic illness, while in other cases viral reactivation or persistence may be the primary culprit, and the two may interact so that initial antiviral responses elicit prolonged autoimmune reactions. Defining the targets recognized by immune responses is critical for identification of patient subgroups with distinct underlying disease mechanisms and enabling precision treatment with immunomodulatory or antiviral therapy. In this project, we will apply novel single-cell profiling technologies to characterize immune repertoires and identify targets of B and T cell responses in ME/CFS and long COVID patients. By identifying autoantigens and viral targets of these immune responses, we will gain insight into underlying disease mechanisms defining patient subgroups that can be translated into diagnostic biomarkers and therapeutic interventions. About HiFiBiO Therapeutics HiFiBiO Therapeutics is a clinical stage global biotech pioneering a unique high-resolution translational platform (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® platform and has been recognized as one of 2023’s Fierce 15 biotech companies. Additional information can be found at www.hifibio.com. HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates. About the Selin Lab The Selin Lab is a viral immunology lab at UMass Chan Medical School focused on understanding human adaptive immune response. Liisa K. Selin’s lab studies T cell response in multiple neuroinflammatory, infection-associated chronic illnesses, such as ME/CFS, long COVID and Multiple Sclerosis. The Selin Lab seeks to conduct clinically significant research in order to advance diagnostics and treatment for these complex and chronic conditions.

晶核生物医药科技（南京）有限公司（以下简称“晶核生物”）宣布完成近亿元人民币的天使轮融资。本轮领投方为高榕资本，跟投方包括VI Ventures、骊宸资本及老股东凯泰资本。 晶核生物医药科技（南京）有限公司（以下简称“晶核生物”）宣布完成近亿元人民币的天使轮融资。本轮领投方为高榕资本，跟投方包括VI Ventures、骊宸资本及老股东凯泰资本。此前，公司已完成数千万人民币的种子轮融资，领投方为凯泰资本和沂景资本。   本轮融资资金主要用于加速将晶核生物在研多个创新靶向核药推向临床阶段，并升级核药研发平台，进一步巩固其在靶向核药领域的领先地位。   晶核生物是一家专注于可视化诊疗一体靶向放射性核素疗法（TRT）开发的生物医药企业，拥有靶向配体筛选、放射性药物偶联、药物临床转化三大技术平台，致力于造福全球的癌症和其它类重疾病患者。   晶核生物于2021年由余海华博士、王羽博士等四位创始人联合创立，余海华博士曾就职于GSK，从事新药研发10多年，后加入华益科技，负责分子影像与药物研究院；王羽博士曾在Endocyte（已被Novartis并购）、Eli Lilly等国际知名药企从事小分子核药等各种靶向偶联药物研发20余年，具有美国多个NDA和IND的新药研发经验。   晶核生物联合创始人余海华博士表示：“此次得到高榕资本、VI Ventures等国际知名风投机构新一轮投资，也得到老股东的继续信任和支持，在‘资本寒冬’的大环境下，不仅是对晶核生物团队和项目的认可与肯定，也是对可视化诊疗一体靶向核药物领域的看好。可视化诊疗一体靶向核药通过借助PET/CT等设备既能实现全身动态、无创伤的早期可视化诊断和评级，又能实现治疗效果的评价；同时，靶向放射性治疗药物（TRT）充分结合了靶向药物和物理射线的优势，从用药剂量、安全性及克服耐药性等方面解决了当前的临床痛点，为国内外患者提供一种全新的药物选择。”   高榕资本刘静逸博士表示：“靶向核药作为全球范围内的一种新型差异化治疗方式，有着非常广阔的市场前景。作为新兴领域，靶向核药跟传统药物的开发思路和筛选评价有较大差异，面临的问题和挑战更多，技术壁垒更高。晶核生物创始团队来自业内明星企业Endocyte/Novartis，Siemens，GSK, 华益等，且已有国际已上市核药的研发经验，相信团队能充分利用技术平台优势，加速产品管线的开发进程，早日为全球患者带来新的希望。”   凯泰资本执行总裁俞广为表示：“晶核生物的联合创始团队具有全球一线水平的靶向核素药物研发经验，从临床前靶向配体筛选、偶联技术应用、放射性药物优化、热化学CMC等全流程开发经历，同时借助自身多功能偶联技术平台（J-Linker），为晶核生物后期的研发提供了强有利的创新源动力和竞争优势。”   VI Ventures副总裁周文喆表示：“治疗性靶向核药是一个高门槛、高准入的领域，目前还是一个相对较新的赛道，从国内外已上市的药物数量来看，这个领域还是一片蓝海，具有很大的市场前景。新的领域意味着新的挑战，相信晶核的团队有实力从这个领域脱颖而出，成为该领域的全球引领者。”   关于晶核生物   晶核生物成立于2021年，联合创始团队来自Endocyte、Siemens、Lily、Roche、GSK等知名国际药企，具有丰富的创新核药开发经验。公司致力于引领和推动中国创新核药的发展，秉承“患者需求导向”、“精益求‘晶’”的理念，借助自身经验和技术平台，力争为全球患者带来更加安全有效的创新药物。   关于高榕资本   高榕资本专注于早期和成长期投资，重点投资新消费、新技术、医疗健康等创新创业领域。在医疗健康领域，投资数字健康、医疗服务、新药研发、医疗器械及检测等方向的优秀企业；在新技术领域，高榕深耕人工智能、智能硬件、机器人、芯片、企业服务与产业升级等新技术领域；新消费领域，持续寻找“新电商”、“新零售”、“新品牌”、“新娱乐”和“新基础设施”领域的机会。截至目前，高榕已投资国内外200+家企业，已有20+家企业完成上市，独角兽企业30+家估值超过10亿美金。   关于凯泰资本   凯泰资本是一家创新资本管理机构，专注于生物医药与生命科学、人工智能与数字科技、数据智能与科技消费等方向的投资。凯泰资本在生物医药与生命科学领域以全球化的视野、前瞻性的行业研究和产业生态投资理念，已投资布局国内外生物医药和生命科学企业100多家，初步形成了产业协作生态。在肿瘤、自身免疫性疾病、代谢性疾病、抗感染、呼吸系统疾病、心血管疾病、神经科学、肾病、眼科、皮肤以及基因治疗与细胞药物、医药工业、创新的生物技术及大健康产业方向形成了生态化的投资组合。   关于沂景资本   沂景资本成立于2015年，总部位于上海，是一支专注于全球范围内医疗健康、前沿科技、新消费领域的专业投资机构，并同时运作上述领域的母基金投资。公司秉持“帮助企业创新成长，促进产业优化升级，推动社会发展进步”的理念，发展至今管理规模已达80亿人民币，行业公认的独角兽企业已达8家。沂景资本投资项目中，众多企业已发展成各自细分领域具有影响力的领先企业，医疗健康领域包括捍宇医疗、大医集团、奥浦迈、梅斯医学、唯儿诺儿科等；前沿科技领域包括壁仞科技、零跑汽车、曦智科技、千寻位置、思朗科技、昕原半导体等；新消费领域包括隅田川咖啡、直客通等。   关于VI Ventures   弘励创投关注海内外具有创业热情和领先技术的公司，为其提供种子、初创直至成长阶段的资金。主要投资生物医药、医疗器械和生物科技及TMT领域，投资范围遍布中国、美国和以色列。旨在帮助投资组合中的境外公司进入正在蓬勃发展的中国市场，同时架设国内公司业务向境外扩展的桥梁。天使轮孵化或早期投资组合包括：Hifibio、Viracta Therapeutics、Rani Therapeutics、Aadi biosciences、糖吉医疗、绘云生物、劲风生物、Platelet Biogenesis、厚凯医疗、Apexigen、泰励生物、TriArm、奥素液芯等。